Curated News
By: NewsRamp Editorial Staff
May 18, 2026

Oragenics Advances Concussion Drug ONP-002 in Phase IIa Trial

Discuss on Substack View History of this news story on GitHub
Original Source

TLDR

  • Oragenics advances Phase IIa concussion trial, targeting FDA meeting in 2025 and IND submission by 2026 for first-in-class treatment.
  • ONP-002 is delivered intranasally to the brain; Phase IIa enrolling in Australia, with U.S. regulatory steps planned through 2026.
  • Oragenics aims to address unmet needs in traumatic brain injury, potentially improving outcomes for concussion patients worldwide.
  • Oragenics also plans to license a CNS medical device, expanding its pipeline beyond the lead concussion therapy.

Impact - Why it Matters

This news matters because concussions and mild traumatic brain injuries affect millions worldwide, yet no FDA-approved treatments exist. Oragenics’ ONP-002 could become the first therapy to directly target the underlying brain injury, potentially reducing long-term cognitive impairments and improving recovery outcomes. The company’s progress in Australia and planned U.S. regulatory steps signal a possible breakthrough in neurological care, offering hope to patients, athletes, and military personnel who suffer from repeated head trauma.

Summary

Oragenics (NYSE American: OGEN) is making significant strides in the fight against concussions and mild traumatic brain injury (mTBI), as detailed in a recent shareholder update. The company is actively enrolling and dosing patients in its Phase IIa clinical trial of ONP-002, a potential first-in-class treatment delivered via proprietary intranasal technology. The trial is underway across multiple sites in Australia, and Oragenics is simultaneously advancing U.S. regulatory preparations. The company plans to request a Type C FDA meeting in the second quarter of 2026, with an Investigational New Drug (IND) submission targeted by year-end 2026. This dual-track approach aims to accelerate the development of ONP-002, which could address a critical unmet medical need in neurological care.

In addition to its clinical progress, Oragenics disclosed a letter of intent to pursue licensing of a complementary CNS-related medical device, signaling potential expansion of its product pipeline. The company reported a cash balance of $6.1 million as of March 31, 2026, providing runway for upcoming milestones. Oragenics’ intranasal delivery platform has broad applications, including Parkinson’s, Alzheimer’s, PTSD, and anxiety disorders, positioning the company for long-term impact in neurology. For more details, the full press release is available at https://ibn.fm/tEk2C.

Oragenics is a clinical-stage biotechnology company focused on brain-targeted therapeutics. Its lead candidate, ONP-002, aims to be the first treatment specifically designed for concussion and mTBI. The company’s intranasal delivery platform may offer a non-invasive route to the brain, potentially reducing side effects and improving outcomes. Investors can find the latest updates in the company’s newsroom at https://ibn.fm/OGEN. The news release was distributed by BioMedWire, a specialized communications platform within the Dynamic Brand Portfolio @ IBN, which provides corporate communications solutions and press distribution services.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Oragenics Advances Concussion Drug ONP-002 in Phase IIa Trial

blockchain registration record for this content.